Capricor Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics for the treatment of diseases. Its lead programs target post myocardial infarction (heart attack), heart failure and Duchenne Muscular Dystrophy. As a developer of innovative therapies, Capricor Therapeutics is strategically positioned at the forefront of one of the largest segments of the U.S. healthcare industry − cardiovascular disease.
Type
Public
HQ
Beverly Hills, US
Founded
2005
Size (employees)
29 (est)
Capricor Therapeutics was founded in 2005 and is headquartered in Beverly Hills, US
Report incorrect company information

Key People/Management at Capricor Therapeutics

Linda Marbán

Linda Marbán

President, CEO and Director
AJ Bergmann

AJ Bergmann

Chief Financial Officer
Deborah Ascheim

Deborah Ascheim

Chief Medical Officer
Jeffrey Rudy

Jeffrey Rudy

Vice President of Clinical Operations
Rachel Smith

Rachel Smith

Vice President of Research and Development
J.D Karen Krasney

J.D Karen Krasney

Executive Vice President and General Counsel
Luis Martinez

Luis Martinez

Vice President of Regenerative Therapies

Capricor Therapeutics Office Locations

Capricor Therapeutics has an office in Beverly Hills
Beverly Hills, US (HQ)
8840 Wilshire Blvd
Show all (1)
Report incorrect company information

Capricor Therapeutics Financials and Metrics

Capricor Therapeutics Financials

Capricor Therapeutics's revenue was reported to be $4 m in FY, 2016 which is a 27.5% decrease from the previous period.
USD

Revenue (Q3, 2017)

313.3 k

Net income (Q3, 2017)

(2.7 m)

EBIT (Q3, 2017)

(2.6 m)

Market capitalization (5-Feb-2018)

43.2 m

Cash (2-Feb-2018)

8.9 m
Capricor Therapeutics's current market capitalization is $43.2 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

503.2 k4.8 m5.5 m4 m

Revenue growth, %

851%15%(28%)

General and administrative expense

2.2 m

R&D expense

5.2 m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

1 m1 m1.3 m1.8 m1.3 m1.3 m1.2 m1.1 m746.8 k880.8 k996.5 k313.3 k

General and administrative expense

852.3 k665.7 k819.7 k1.4 m926.3 k972.8 k1.1 m1.4 m1.3 m1.2 m1.2 m1.1 m

R&D expense

1.4 m1.9 m2 m3.8 m3.4 m3.2 m4.3 m4.3 m4.7 m3.3 m3.1 m1.9 m

Operating expense total

2.2 m2.5 m2.8 m5.2 m4.4 m4.2 m5.4 m5.7 m6 m4.4 m4.4 m3 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

1.7 m8 m5.6 m3.2 m

Accounts Receivable

187

Inventories

222.8 k235.5 k210.6 k342.9 k

Current Assets

3.7 m11.6 m14 m18.1 m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

13 m11.6 m9.8 m6.9 m5 m4.2 m11.8 m8.9 m18 m2.8 m8.3 m8.9 m

Accounts Receivable

757 230 823

Inventories

190.3 k

Current Assets

14 m16.4 m14.2 m25.4 m21.6 m17.7 m14.9 m11.8 m22.4 m13.5 m13.6 m15.2 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(8.9 m)(6.2 m)(12.9 m)(18.8 m)

Depreciation and Amortization

26.9 k41.9 k110.9 k125.7 k

Inventories

(161.6 k)(12.6 k)24.9 k(132.3 k)

Accounts Payable

974.7 k70.3 k831.2 k508.3 k
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(1.2 m)(1.5 m)(1.5 m)(3.5 m)(3.1 m)(2.9 m)(4.3 m)(4.7 m)(5.3 m)(3.7 m)

Accounts Payable

339.2 k1.7 m1.6 m2.7 m2.7 m2.3 m3.2 m2.9 m3.9 m2.5 m
USDY, 2017

Financial Leverage

-3.7 x
Show all financial metrics
Report incorrect company information